Mesenchymal stem cell treatments appear generally safe, but benefits in ALS remain uncertain
Original source
Advances in the clinical application of mesenchymal stem cells for neurological disorders. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Review
- Studied in
- Human, Animal
A review of clinical studies found that mesenchymal stem cell treatments have generally shown a favorable safety profile across neurological disorders, including amyotrophic lateral sclerosis (ALS). However, treatment benefits have varied between studies and have not been consistently demonstrated. Differences in cell preparation, delivery, dosing and patient selection may help explain the mixed results.
Why this matters
This means mesenchymal stem cell treatment remains an area of research rather than an established ALS treatment. Larger, rigorously designed randomized trials and more consistent treatment protocols are needed to determine whether it benefits people with ALS.
Limitations and context
This is a review of existing clinical evidence, not a new clinical trial. The review describes inconsistent effectiveness across studies and substantial differences in how treatments were prepared and delivered, so it does not establish whether mesenchymal stem cells improve outcomes in ALS.